Intra-Cellular Therapies Total Liabilities 2013-2022 | ITCI

Intra-Cellular Therapies total liabilities from 2013 to 2022. Total liabilities can be defined as the total value of all possible claims against the corporation.
  • Intra-Cellular Therapies total liabilities for the quarter ending March 31, 2022 were $0.076B, a 21.64% increase year-over-year.
  • Intra-Cellular Therapies total liabilities for 2021 were $0.072B, a 19.15% increase from 2020.
  • Intra-Cellular Therapies total liabilities for 2020 were $0.06B, a 7.61% increase from 2019.
  • Intra-Cellular Therapies total liabilities for 2019 were $0.056B, a 42.25% increase from 2018.
Intra-Cellular Therapies Annual Total Liabilities
(Millions of US $)
2021 $72
2020 $60
2019 $56
2018 $39
2017 $17
2016 $13
2015 $8
2014 $11
2013 $7
2012 $3
Intra-Cellular Therapies Quarterly Total Liabilities
(Millions of US $)
2022-03-31 $76
2021-12-31 $72
2021-09-30 $70
2021-06-30 $72
2021-03-31 $62
2020-12-31 $60
2020-09-30 $62
2020-06-30 $61
2020-03-31 $51
2019-12-31 $56
2019-09-30 $54
2019-06-30 $53
2019-03-31 $54
2018-12-31 $39
2018-09-30 $32
2018-06-30 $22
2018-03-31 $22
2017-12-31 $17
2017-09-30 $15
2017-06-30 $10
2017-03-31 $19
2016-12-31 $13
2016-09-30 $143
2016-06-30 $22
2016-03-31 $11
2015-12-31 $8
2015-09-30 $11
2015-06-30 $10
2015-03-31 $15
2014-12-31 $11
2014-09-30 $4
2014-06-30 $3
2014-03-31 $4
2013-12-31 $7
2013-09-30 $8
2013-06-30 $0
2013-03-31 $0
2012-12-31
2012-09-30 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.204B $0.084B
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00